SG10201402742YA - Bispecific anti-her antibodies - Google Patents

Bispecific anti-her antibodies

Info

Publication number
SG10201402742YA
SG10201402742YA SG10201402742YA SG10201402742YA SG10201402742YA SG 10201402742Y A SG10201402742Y A SG 10201402742YA SG 10201402742Y A SG10201402742Y A SG 10201402742YA SG 10201402742Y A SG10201402742Y A SG 10201402742YA SG 10201402742Y A SG10201402742Y A SG 10201402742YA
Authority
SG
Singapore
Prior art keywords
antibodies
bispecific anti
bispecific
anti
Prior art date
Application number
SG10201402742YA
Inventor
Germaine Fuh
Gabriele Schaefer
Lauric Haber
Mark X Sliwkowski
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to US21056209P priority Critical
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of SG10201402742YA publication Critical patent/SG10201402742YA/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507Comprising a combination of two or more separate antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/30Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565Complementarity determining region [CDR]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732Antibody-dependent cellular cytotoxicity [ADCC]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/90Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
SG10201402742YA 2009-03-20 2010-03-19 Bispecific anti-her antibodies SG10201402742YA (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US21056209P true 2009-03-20 2009-03-20

Publications (1)

Publication Number Publication Date
SG10201402742YA true SG10201402742YA (en) 2014-08-28

Family

ID=42111063

Family Applications (2)

Application Number Title Priority Date Filing Date
SG10201402742YA SG10201402742YA (en) 2009-03-20 2010-03-19 Bispecific anti-her antibodies
SG2011066115A SG174378A1 (en) 2009-03-20 2010-03-19 Bispecific anti-her antibodies

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG2011066115A SG174378A1 (en) 2009-03-20 2010-03-19 Bispecific anti-her antibodies

Country Status (27)

Country Link
US (4) US20120121596A1 (en)
EP (2) EP2408817B1 (en)
JP (2) JP5624114B2 (en)
KR (3) KR20130080871A (en)
CN (2) CN102356092B (en)
AR (1) AR075896A1 (en)
AU (1) AU2010226453B2 (en)
BR (1) BRPI1006215A2 (en)
CA (1) CA2755640C (en)
CL (1) CL2011002304A1 (en)
CO (1) CO6430487A2 (en)
CR (1) CR20110496A (en)
EC (1) ECSP11011338A (en)
ES (1) ES2572728T3 (en)
HK (2) HK1165809A1 (en)
IL (2) IL214827A (en)
MA (1) MA33198B1 (en)
MX (1) MX2011009729A (en)
MY (1) MY152068A (en)
NZ (1) NZ594665A (en)
PE (1) PE05392012A1 (en)
RU (2) RU2504553C2 (en)
SG (2) SG10201402742YA (en)
TW (3) TWI461211B (en)
UA (1) UA106070C2 (en)
WO (1) WO2010108127A1 (en)
ZA (1) ZA201106127B (en)

Families Citing this family (79)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2399075T3 (en) 2006-08-30 2013-03-25 Genentech, Inc. multispecific antibodies
AU2008230795B2 (en) 2007-03-27 2014-05-29 I2 Pharmaceuticals, Inc. Constructs and libraries comprising antibody surrogate light chain sequences
US20090162359A1 (en) 2007-12-21 2009-06-25 Christian Klein Bivalent, bispecific antibodies
EP2257293A2 (en) * 2008-03-06 2010-12-08 Genentech, Inc. Combination therapy with c-met and egfr antagonists
MY152068A (en) * 2009-03-20 2014-08-15 Genentech Inc Bispecific anti-her antibodies
CN102482345A (en) 2009-05-13 2012-05-30 航道生物技术有限责任公司 Neutralizing molecules to influenza viruses
US9676845B2 (en) 2009-06-16 2017-06-13 Hoffmann-La Roche, Inc. Bispecific antigen binding proteins
WO2011076683A1 (en) 2009-12-22 2011-06-30 Roche Glycart Ag Anti-her3 antibodies and uses thereof
CN102892779B (en) 2010-02-18 2016-12-21 基因泰克公司 Neuregulin antagonists and their use in the treatment of cancer
RU2624027C2 (en) 2010-04-23 2017-06-30 Дженентек, Инк. Heteromultimeric proteins production
US20130058947A1 (en) 2011-09-02 2013-03-07 Stem Centrx, Inc Novel Modulators and Methods of Use
TW201302793A (en) 2010-09-03 2013-01-16 Glaxo Group Ltd Novel antigen binding proteins
PL2635604T3 (en) * 2010-11-01 2017-09-29 Symphogen A/S Pan-her antibody composition
US9155802B2 (en) 2010-11-01 2015-10-13 Symphogen A/S Pan-HER antibody composition
CN103260647A (en) * 2010-11-30 2013-08-21 伦敦健康科学中心研究公司 EGFR antagonist for the treatment of heart disease
ES2549638T3 (en) 2011-02-28 2015-10-30 F. Hoffmann-La Roche Ag Antigen binding proteins
KR20140044796A (en) 2011-03-11 2014-04-15 메리맥 파마슈티컬즈, 인크. Use of inhibitors of egfr-family receptors in the treatment of hormone refractory breast cancers
AU2012229062A1 (en) * 2011-03-15 2013-04-11 Merrimack Pharmaceuticals, Inc. Overcoming resistance to ErbB pathway inhibitors
EP2710040B1 (en) 2011-05-19 2017-07-12 INSERM (Institut National de la Santé et de la Recherche Medicale) Anti-human-her3 antibodies and uses thereof
US10300140B2 (en) * 2011-07-28 2019-05-28 I2 Pharmaceuticals, Inc. Sur-binding proteins against ERBB3
JP2014526891A (en) 2011-08-17 2014-10-09 ジェネンテック, インコーポレイテッド Neuregulin antibodies and their use
BR112014004762A2 (en) 2011-08-31 2018-06-19 Genentech Inc methods of determining tumor cell growth sensitivity to inhibition by an egfr kinase inhibitor, identifying a cancer patient who is likely to benefit from treatment with an efgr inhibitor, treating cancer in a patient, selecting a therapy for a cancer patient and determining erbb2 gene overexpression in a cell
CN103917562B (en) 2011-09-30 2016-07-06 瑞泽恩制药公司 Anti-antibodies and use -ErbB3
US9273143B2 (en) 2011-09-30 2016-03-01 Regeneron Pharmaceuticals, Inc. Methods and compositions comprising a combination of an anti-ErbB3 antibody and an anti-EGFR antibody
MX2014003698A (en) 2011-09-30 2014-07-28 Genentech Inc Diagnostic methylation markers of epithelial or mesenchymal phenotype and response to egfr kinase inhibitor in tumours or tumour cells.
SG11201402536PA (en) 2011-11-23 2014-06-27 Medimmune Llc Binding molecules specific for her3 and uses thereof
RU2014126098A (en) 2011-11-30 2016-01-27 Дженентек, Инк. Mutations of ErbB3 in Cancer
WO2013096828A1 (en) 2011-12-22 2013-06-27 Sea Lane Biotechnologies, Llc Surrogate binding proteins
JP2015514710A (en) * 2012-03-27 2015-05-21 ジェネンテック, インコーポレイテッド Diagnosis and treatment of HER3 inhibitors
LT2838918T (en) 2012-04-20 2019-09-10 Merus N.V. Methods and means for the production of heterodimeric ig-like molecules
US9527913B2 (en) 2012-05-02 2016-12-27 Symphogen A/S Humanized pan-HER antibody compositions
CN104583239B (en) 2012-05-10 2018-09-18 生物蛋白有限公司 More specific monoclonal antibodies
TR201810930T4 (en) 2012-05-18 2018-08-27 Genentech Inc High concentrations of monoclonal antibody formulations.
EP2855531A1 (en) * 2012-05-24 2015-04-08 F.Hoffmann-La Roche Ag Multispecific antibodies
TWI641619B (en) * 2012-06-25 2018-11-21 美商再生元醫藥公司 Anti-egfr antibodies and uses thereof
EP3401337A1 (en) 2012-09-25 2018-11-14 Glenmark Pharmaceuticals S.A. Purification of hetero-dimeric immunoglobulins
WO2014051433A1 (en) 2012-09-27 2014-04-03 Merus B.V. BISPECIFIC IgG ANTIBODIES AS T CELL ENGAGERS
EP2727942A1 (en) 2012-11-05 2014-05-07 MAB Discovery GmbH Bispecific antibodies against human EGFR, HER2, and HER3
EP2727941A1 (en) 2012-11-05 2014-05-07 MAB Discovery GmbH Method for the production of multispecific antibodies
US20150259430A1 (en) 2012-11-05 2015-09-17 Mab Discovery Gmbh Method for the production of multispecific antibodies
EP2727943A1 (en) 2012-11-05 2014-05-07 MAB Discovery GmbH Trispecific antibodies against human EGFR, HER2 and HER3
EA201500503A1 (en) 2012-11-08 2015-10-30 Ф.Хоффманн-Ля Рош Аг Anti-her3 / her4 antigen-binding proteins connecting a her3 beta hair and her4 beta heel
KR20150092760A (en) 2012-12-07 2015-08-13 더 제너럴 하스피탈 코포레이션 Combinations of a pi3k/akt inhibitor compound with an her3/egfr inhibitor compound and use thereof in the treatment of a hyperproliferative disorder
AR094403A1 (en) * 2013-01-11 2015-07-29 F Hoffmann-La Roche Ag Combination therapy of anti-HER3
EP2954056A4 (en) 2013-02-08 2016-09-21 Stemcentrx Inc Novel multispecific constructs
CA2903480A1 (en) 2013-03-14 2014-09-25 Genentech, Inc. Combinations of a mek inhibitor compound with an her3/egfr inhibitor compound and methods of use
CA2911961A1 (en) 2013-05-14 2014-11-20 Board Of Regents, The University Of Texas System Human application of engineered chimeric antigen receptor (car) t-cells
SG11201509609SA (en) 2013-05-24 2015-12-30 Univ Texas Chimeric antigen receptor-targeting monoclonal antibodies
EP2821071A1 (en) 2013-07-04 2015-01-07 Institut d'Investigació Biomèdica de Bellvitge (IDIBELL) Compounds for breast cancer treatment
KR20150014551A (en) 2013-07-29 2015-02-09 삼성전자주식회사 Anti-EGFR scFv fragment and Bispecific anti-c-Met/anti-EGFR antibodies comprising the same
KR20160044060A (en) 2013-10-11 2016-04-22 에프. 호프만-라 로슈 아게 Multispecific domain exchanged common variable light chain antibodies
CA2929256A1 (en) 2013-11-04 2015-05-07 Glenmark Pharmaceuticals S.A. Production of t cell retargeting hetero-dimeric immunoglobulins
CA2929386A1 (en) 2013-11-07 2015-05-14 Inserm (Institut National De La Sante Et De La Recherche Medicale) Neuregulin allosteric anti-her3 antibody
CA2931113A1 (en) * 2013-12-20 2015-06-25 Genentech, Inc. Dual specific antibodies
KR20160145560A (en) 2014-02-28 2016-12-20 메뤼스 엔.페. Antibody that binds erbb-2 and erbb-3
EP3110846A1 (en) * 2014-02-28 2017-01-04 Merus N.V. Antibodies that bind egfr and erbb3
EA201691824A1 (en) 2014-03-11 2016-12-30 Регенерон Фармасьютикалс, Инк. Antibodies against egfrviii and their applications
KR20160137599A (en) 2014-03-24 2016-11-30 제넨테크, 인크. Cancer treatment with c-met antagonists and correlation of the latter with hgf expression
FR3020063A1 (en) 2014-04-16 2015-10-23 Gamamabs Pharma Anti-her4 human antibody
KR20150128367A (en) 2014-05-09 2015-11-18 삼성전자주식회사 Anti-cMET/anti-EGFR/anti-HER3 multipecific antibodies and uses thereof
TW201625684A (en) 2014-06-26 2016-07-16 Macrogenics Inc Diabody immunoreactive with pd-1 and the lag-3 covalently bound and methods of use thereof
JP2017535284A (en) 2014-11-05 2017-11-30 ボード・オブ・リージエンツ,ザ・ユニバーシテイ・オブ・テキサス・システム Genetically modified immune effector cells and genetically engineered cells for expansion of immune effector cells
CA2964783A1 (en) * 2014-11-05 2016-05-12 Board Of Regents, The University Of Texas System Chimeric antigen receptors (car) to selectively target protein complexes
CA2990305A1 (en) 2015-06-26 2016-12-29 Mab Discovery Gmbh Monoclonal anti-il-1racp antibodies
US9914777B2 (en) 2015-07-10 2018-03-13 Merus N.V. Human CD3 binding antibody
TW201716439A (en) 2015-07-20 2017-05-16 Lilly Co Eli Her3 antibody
WO2017019846A1 (en) 2015-07-30 2017-02-02 Macrogenics, Inc. Pd-1-binding molecules and methods use thereof
CN106729743A (en) 2015-11-23 2017-05-31 四川科伦博泰生物医药股份有限公司 Anti-ErbB2 antibody-drug conjugate, composition, preparation method and application of anti-ErbB2 antibody-drug conjugate
WO2017100642A1 (en) 2015-12-11 2017-06-15 Regeneron Pharmaceuticals, Inc. Methods for reducing or preventing growth of tumors resistant to egfr and/or erbb3 blockade
TW201730212A (en) 2016-02-17 2017-09-01 Macrogenics Inc Ror1- binding molecules and methods of use
US20190091227A1 (en) 2016-03-15 2019-03-28 Merrimack Pharmaceuticals, Inc. Methods for treating er+, her2-, hrg+ breast cancer using combination therapies comprising an anti-erbb3 antibody
EP3241845A1 (en) 2016-05-06 2017-11-08 MAB Discovery GmbH Humanized anti-il-1r3 antibodies
US10167342B2 (en) 2016-08-29 2019-01-01 Fazel Shokri Production of hersintuzumab: a new humanized antibody against HER2 for cancer treatment
CA3053749A1 (en) 2017-02-28 2018-09-07 Kinki University Method for treating egfr-tki-resistant non-small cell lung cancer by administration of anti-her3 antibody-drug conjugate
WO2018182421A1 (en) 2017-03-31 2018-10-04 Merus N.V. Erbb-2 targeting agent and a bispecific antibody with antigen-binding sites that bind an epitope on an extracellular part of erb-2 and erbb-3, for treatment of an individual with an erbb-2, erbb-2/erbb-3 positive tumour
EP3401332A1 (en) 2017-05-08 2018-11-14 MAB Discovery GmbH Anti-il-1r3 antibodies for use in inflammatory conditions
WO2018212656A1 (en) 2017-05-17 2018-11-22 Merus N.V. Combination of an erbb-2/erbb-3 bispecific antibody with endocrine therapy for breast cancer
WO2019057792A1 (en) 2017-09-19 2019-03-28 Mab Discovery Gmbh Agonistic cd40 antibodies
WO2019108065A1 (en) 2017-12-01 2019-06-06 Merus N.V. Use of bispecific antibody and il-15 for combination therapy

Family Cites Families (280)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US3896111A (en) 1973-02-20 1975-07-22 Research Corp Ansa macrolides
US4151042A (en) 1977-03-31 1979-04-24 Takeda Chemical Industries, Ltd. Method for producing maytansinol and its derivatives
US4137230A (en) 1977-11-14 1979-01-30 Takeda Chemical Industries, Ltd. Method for the production of maytansinoids
US4265814A (en) 1978-03-24 1981-05-05 Takeda Chemical Industries Matansinol 3-n-hexadecanoate
US4307016A (en) 1978-03-24 1981-12-22 Takeda Chemical Industries, Ltd. Demethyl maytansinoids
JPS5562090A (en) 1978-10-27 1980-05-10 Takeda Chem Ind Ltd Novel maytansinoid compound and its preparation
US4256746A (en) 1978-11-14 1981-03-17 Takeda Chemical Industries Dechloromaytansinoids, their pharmaceutical compositions and method of use
JPS5566585A (en) 1978-11-14 1980-05-20 Takeda Chem Ind Ltd Novel maytansinoid compound and its preparation
JPS55102583A (en) 1979-01-31 1980-08-05 Takeda Chem Ind Ltd 20-acyloxy-20-demethylmaytansinoid compound
JPS55162791A (en) 1979-06-05 1980-12-18 Takeda Chem Ind Ltd Antibiotic c-15003pnd and its preparation
JPS55164685A (en) 1979-06-08 1980-12-22 Takeda Chem Ind Ltd Novel maytansinoid compound and its preparation
JPS55164687A (en) 1979-06-11 1980-12-22 Takeda Chem Ind Ltd Novel maytansinoid compound and its preparation
JPS55164686A (en) 1979-06-11 1980-12-22 Takeda Chem Ind Ltd Novel maytansinoid compound and its preparation
US4309428A (en) 1979-07-30 1982-01-05 Takeda Chemical Industries, Ltd. Maytansinoids
JPS6253158B2 (en) 1979-09-19 1987-11-09 Takeda Chemical Industries Ltd
JPH0115514B2 (en) 1979-09-21 1989-03-17 Takeda Chemical Industries Ltd
EP0028683A1 (en) 1979-09-21 1981-05-20 Takeda Chemical Industries, Ltd. Antibiotic C-15003 PHO and production thereof
WO1982001188A1 (en) 1980-10-08 1982-04-15 Takeda Chemical Industries Ltd 4,5-deoxymaytansinoide compounds and process for preparing same
US4450254A (en) 1980-11-03 1984-05-22 Standard Oil Company Impact improvement of high nitrile resins
US4313946A (en) 1981-01-27 1982-02-02 The United States Of America As Represented By The Secretary Of Agriculture Chemotherapeutically active maytansinoids from Trewia nudiflora
US4315929A (en) 1981-01-27 1982-02-16 The United States Of America As Represented By The Secretary Of Agriculture Method of controlling the European corn borer with trewiasine
JPH0114918B2 (en) 1981-05-20 1989-03-14 Takeda Chemical Industries Ltd
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US6054561A (en) * 1984-02-08 2000-04-25 Chiron Corporation Antigen-binding sites of antibody molecules specific for cancer antigens
US4943533A (en) 1984-03-01 1990-07-24 The Regents Of The University Of California Hybrid cell lines that produce monoclonal antibodies to epidermal growth factor receptor
US4970198A (en) 1985-10-17 1990-11-13 American Cyanamid Company Antitumor antibiotics (LL-E33288 complex)
US7838216B1 (en) 1986-03-05 2010-11-23 The United States Of America, As Represented By The Department Of Health And Human Services Human gene related to but distinct from EGF receptor gene
US5401638A (en) 1986-06-04 1995-03-28 Oncogene Science, Inc. Detection and quantification of neu related proteins in the biological fluids of humans
US4935341A (en) 1986-06-04 1990-06-19 Whitehead Institute For Biomedical Research Detection of point mutations in neu genes
US4968603A (en) 1986-12-31 1990-11-06 The Regents Of The University Of California Determination of status in neoplastic disease
IL85035D0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
US5079233A (en) 1987-01-30 1992-01-07 American Cyanamid Company N-acyl derivatives of the LL-E33288 antitumor antibiotics, composition and methods for using the same
JP3101690B2 (en) 1987-03-18 2000-10-23 エス・ビィ・2・インコーポレイテッド Denaturation antibody, or improvements relating modified antibody
US5606040A (en) 1987-10-30 1997-02-25 American Cyanamid Company Antitumor and antibacterial substituted disulfide derivatives prepared from compounds possessing a methyl-trithio group
US5770701A (en) 1987-10-30 1998-06-23 American Cyanamid Company Process for preparing targeted forms of methyltrithio antitumor agents
US5824311A (en) * 1987-11-30 1998-10-20 Trustees Of The University Of Pennsylvania Treatment of tumors with monoclonal antibodies against oncogene antigens
WO1989006692A1 (en) 1988-01-12 1989-07-27 Genentech, Inc. Method of treating tumor cells by inhibiting growth factor receptor function
US5720937A (en) 1988-01-12 1998-02-24 Genentech, Inc. In vivo tumor detection assay
US20020192211A1 (en) 1998-03-17 2002-12-19 Hudziak Robert M. Method of treating tumor cells by inhibiting growth factor receptor function
US4975278A (en) 1988-02-26 1990-12-04 Bristol-Myers Company Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells
WO1989010412A1 (en) 1988-04-18 1989-11-02 Applied Biotechnology, Inc. Detection of neu gene expression and products
AU4128089A (en) * 1988-09-15 1990-03-22 Rorer International (Overseas) Inc. Monoclonal antibodies specific to human epidermal growth factor receptor and therapeutic methods employing same
US5053394A (en) 1988-09-21 1991-10-01 American Cyanamid Company Targeted forms of methyltrithio antitumor agents
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5175384A (en) 1988-12-05 1992-12-29 Genpharm International Transgenic mice depleted in mature t-cells and methods for making transgenic mice
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
ES2106033T3 (en) 1989-05-19 1997-11-01 Genentech Inc extracellular domain of HER2.
DE3920358A1 (en) 1989-06-22 1991-01-17 Behringwerke Ag Bispecific, oligo, mono- and oligovalent antikoerperkonstrukte, their production and use
US5705157A (en) 1989-07-27 1998-01-06 The Trustees Of The University Of Pennsylvania Methods of treating cancerous cells with anti-receptor antibodies
US6884418B1 (en) 1989-08-04 2005-04-26 Berlex Laboratories, Inc. Use of ligand-mimicking agents and anti-neoplastic drugs in cancer therapy
AT207958T (en) 1989-08-04 2001-11-15 Schering Ag External domain of c-erbB-2: gp75
DE69025946D1 (en) 1989-09-08 1996-04-18 Univ Johns Hopkins Modifications to the structure of the EGF receptor gene in human glioma
DE68926248T2 (en) 1989-09-29 1996-12-19 Oncogene Science Inc p100 "new" human protein metallic and use of this protein for the detection of neoplastic preneoplasmatischen- or in humans
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
CA2026147C (en) 1989-10-25 2006-02-07 Ravi J. Chari Cytotoxic agents comprising maytansinoids and their therapeutic use
US5959177A (en) 1989-10-27 1999-09-28 The Scripps Research Institute Transgenic plants expressing assembled secretory antibodies
US5183884A (en) 1989-12-01 1993-02-02 United States Of America Dna segment encoding a gene for a receptor related to the epidermal growth factor receptor
DE69133566T2 (en) 1990-01-12 2007-12-06 Amgen Fremont Inc. Formation of xenogenic antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
EP0814159B1 (en) 1990-08-29 2005-07-27 GenPharm International, Inc. Transgenic mice capable of producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5571894A (en) 1991-02-05 1996-11-05 Ciba-Geigy Corporation Recombinant antibodies specific for a growth factor receptor
US5939531A (en) 1991-07-15 1999-08-17 Novartis Corp. Recombinant antibodies specific for a growth factor receptor
AU662311B2 (en) 1991-02-05 1995-08-31 Novartis Ag Recombinant antibodies specific for a growth factor receptor
IL101943D0 (en) 1991-05-24 1992-12-30 Genentech Inc Structure,production and use of heregulin
CA2103059C (en) 1991-06-14 2005-03-22 Paul J. Carter Method for making humanized antibodies
US6800738B1 (en) 1991-06-14 2004-10-05 Genentech, Inc. Method for making humanized antibodies
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
CA2096417C (en) 1991-08-22 2000-10-10 Sarah S. Bacus Methods and compositions for cancer therapy and for prognosticating responses to cancer therapy
US7018809B1 (en) 1991-09-19 2006-03-28 Genentech, Inc. Expression of functional antibody fragments
US5288477A (en) 1991-09-27 1994-02-22 Becton, Dickinson And Company Method for prognosticating response to cancer therapy
US5362852A (en) 1991-09-27 1994-11-08 Pfizer Inc. Modified peptide derivatives conjugated at 2-hydroxyethylamine moieties
US5587458A (en) 1991-10-07 1996-12-24 Aronex Pharmaceuticals, Inc. Anti-erbB-2 antibodies, combinations thereof, and therapeutic and diagnostic uses thereof
CA2122732C (en) 1991-11-25 2008-04-08 Marc D. Whitlow Multivalent antigen-binding proteins
AU3236793A (en) 1991-12-12 1993-07-19 Berlex Laboratories, Inc. Recombinant and chimeric antibodies to c-erbB-2
GB9300059D0 (en) 1992-01-20 1993-03-03 Zeneca Ltd Quinazoline derivatives
DE69334351D1 (en) 1992-02-06 2011-05-12 Novartis Vaccines & Diagnostic Biosynthetic binding protein for tumor markers
AU4025193A (en) 1992-04-08 1993-11-18 Cetus Oncology Corporation Humanized C-erbB-2 specific antibodies
ZA9302522B (en) 1992-04-10 1993-12-20 Res Dev Foundation Immunotoxins directed against c-erbB-2(HER/neu) related surface antigens
CA2120745A1 (en) 1992-06-30 1994-01-06 Philip G. Kasprzyk A combination of anti-erbb-2 monoclonal antibodies and method of using
AU5355594A (en) 1992-10-09 1994-05-09 Oncor, Inc. Methods for the detection of chromosome structural abnormalities by (in situ) hybridization to fixed tissue
MD1367C2 (en) 1992-11-13 2000-11-30 Idec Pharmaceuticals Corporation Methods of B-cells lymphoma treatment, anti-CD20 antibodies, hybridoma
CA2103323A1 (en) 1992-11-24 1994-05-25 Gregory D. Plowman Her4 human receptor tyrosine kinase
US5635483A (en) 1992-12-03 1997-06-03 Arizona Board Of Regents Acting On Behalf Of Arizona State University Tumor inhibiting tetrapeptide bearing modified phenethyl amides
US5780588A (en) 1993-01-26 1998-07-14 Arizona Board Of Regents Elucidation and synthesis of selected pentapeptides
PT616812E (en) 1993-03-24 2000-04-28 Berlex Biosciences Combination of anti-hormonal compounds and ligacation molecules in cancer treatment
WO1994022478A1 (en) 1993-03-30 1994-10-13 The Trustees Of The University Of Pennsylvania PREVENTION OF TUMORS WITH MONOCLONAL ANTIBODIES AGAINST $i(NEU)
CA2163345A1 (en) 1993-06-16 1994-12-22 Susan Adrienne Morgan Antibodies
GB9314893D0 (en) 1993-07-19 1993-09-01 Zeneca Ltd Quinazoline derivatives
PT659439E (en) 1993-12-24 2002-04-29 Merck Patent Gmbh Imunoconjugados
IL112249A (en) 1994-01-25 2001-11-25 Warner Lambert Co Pharmaceutical compositions containing di and tricyclic pyrimidine derivatives for inhibiting tyrosine kinases of the epidermal growth factor receptor family and some new such compounds
US5654307A (en) 1994-01-25 1997-08-05 Warner-Lambert Company Bicyclic compounds capable of inhibiting tyrosine kinases of the epidermal growth factor receptor family
IL112248D0 (en) 1994-01-25 1995-03-30 Warner Lambert Co Tricyclic heteroaromatic compounds and pharmaceutical compositions containing them
US6524832B1 (en) * 1994-02-04 2003-02-25 Arch Development Corporation DNA damaging agents in combination with tyrosine kinase inhibitors
US6811779B2 (en) 1994-02-10 2004-11-02 Imclone Systems Incorporated Methods for reducing tumor growth with VEGF receptor antibody combined with radiation and chemotherapy
US20030108545A1 (en) 1994-02-10 2003-06-12 Patricia Rockwell Combination methods of inhibiting tumor growth with a vascular endothelial growth factor receptor antagonist
US5773001A (en) 1994-06-03 1998-06-30 American Cyanamid Company Conjugates of methyltrithio antitumor agents and intermediates for their synthesis
US5910486A (en) 1994-09-06 1999-06-08 Uab Research Foundation Methods for modulating protein function in cells using, intracellular antibody homologues
US5846749A (en) 1994-10-12 1998-12-08 The Regents Of The University Of California Quantitative measurement of tissue protein identified by immunohistochemistry and standardized protein determination
US5804396A (en) 1994-10-12 1998-09-08 Sugen, Inc. Assay for agents active in proliferative disorders
US5789199A (en) 1994-11-03 1998-08-04 Genentech, Inc. Process for bacterial production of polypeptides
US6214388B1 (en) 1994-11-09 2001-04-10 The Regents Of The University Of California Immunoliposomes that optimize internalization into target cells
AT170082T (en) 1994-11-10 1998-09-15 Univ Eberhard Karls A method for inhibiting the growth of leukemic cells by HER-2 protein-line
CU22545A1 (en) 1994-11-18 1999-03-31 Centro Inmunologia Molecular Obtaining a chimeric and humanized antibody against the epidermal growth factor receptor for diagnostic and therapeutic use
EP0794792A1 (en) 1994-12-02 1997-09-17 Chiron Corporation Method of promoting an immune response with a bispecific antibody
US5663149A (en) 1994-12-13 1997-09-02 Arizona Board Of Regents Acting On Behalf Of Arizona State University Human cancer inhibitory pentapeptide heterocyclic and halophenyl amides
US5840523A (en) 1995-03-01 1998-11-24 Genetech, Inc. Methods and compositions for secretion of heterologous polypeptides
US5783404A (en) 1995-04-13 1998-07-21 Amgen Inc. Methods and compositions for determining HER-2/neu expression using monoclonal antibodies
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
EP1709970A1 (en) 1995-04-27 2006-10-11 Abgenix, Inc. Human antibodies against EGFR, derived from immunized xenomice
GB9508538D0 (en) 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
CA2219486A1 (en) 1995-04-28 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5712374A (en) 1995-06-07 1998-01-27 American Cyanamid Company Method for the preparation of substantiallly monomeric calicheamicin derivative/carrier conjugates
US5714586A (en) 1995-06-07 1998-02-03 American Cyanamid Company Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates
CA2222231A1 (en) 1995-06-07 1996-12-19 Imclone Systems Incorporated Antibody and antibody fragments for inhibiting the growth of tumors
US6410690B1 (en) 1995-06-07 2002-06-25 Medarex, Inc. Therapeutic compounds comprised of anti-Fc receptor antibodies
WO1997000271A1 (en) 1995-06-14 1997-01-03 The Regents Of The University Of California Novel high affinity human antibodies to tumor antigens
TR199800012T1 (en) 1995-07-06 1998-04-21 Novartis Ag Piroloprimid days for preparation and administration.
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
US6685940B2 (en) 1995-07-27 2004-02-03 Genentech, Inc. Protein formulation
DE19544393A1 (en) 1995-11-15 1997-05-22 Hoechst Schering Agrevo Gmbh A synergistic herbicidal mixtures
US5783186A (en) 1995-12-05 1998-07-21 Amgen Inc. Antibody-induced apoptosis
US5760041A (en) 1996-02-05 1998-06-02 American Cyanamid Company 4-aminoquinazoline EGFR Inhibitors
GB9603095D0 (en) 1996-02-14 1996-04-10 Zeneca Ltd Quinazoline derivatives
GB9603256D0 (en) 1996-02-16 1996-04-17 Wellcome Found Antibodies
TW517061B (en) * 1996-03-29 2003-01-11 Pharmacia & Amp Upjohn Ab Modified/chimeric superantigens and their use
US5968511A (en) 1996-03-27 1999-10-19 Genentech, Inc. ErbB3 antibodies
EE05289B1 (en) 1996-04-12 2010-04-15 Warner-Lambert Company Irreversible inhibitors of tyrosine kinases, a pharmaceutical composition for the use of
US5747498A (en) 1996-05-28 1998-05-05 Pfizer Inc. Alkynyl and azido-substituted 4-anilinoquinazolines
US5925519A (en) 1996-06-03 1999-07-20 The Regents Of The University Of California Genetic alterations associated with prostate cancer
US5922845A (en) 1996-07-11 1999-07-13 Medarex, Inc. Therapeutic multispecific compounds comprised of anti-Fcα receptor antibodies
WO1998002434A1 (en) 1996-07-13 1998-01-22 Glaxo Group Limited Fused heterocyclic compounds as protein tyrosine kinase inhibitors
ID18494A (en) 1996-10-02 1998-04-16 Novartis Ag Pirazola derivative fused and the manufacturing process
EP1106183A3 (en) 1996-10-18 2001-09-12 Board Of Regents University Of Texas System Antibodies to erbB2 and their therapeutic uses
US6468547B1 (en) 1996-10-30 2002-10-22 Uab Research Foundation Enhancement of tumor cell chemosensitivity and radiosensitivity using single chain secretory antibodies
AU5243198A (en) 1996-10-30 1998-05-22 Uab Research Foundation, The Enhancement of tumor cell chemosensitivity and radiosensitivity using single chain intracellular antibodies
DE69738075D1 (en) 1996-11-27 2007-10-11 Genentech Inc Affinity purification of polypeptides to a protein-a-matrix
ES2301183T3 (en) 1996-12-03 2008-06-16 Amgen Fremont Inc. completely human antibody binds to EGFR receptor.
US20030171551A1 (en) 1997-01-31 2003-09-11 Joseph D. Rosenblatt Chimeric antibody fusion proteins for the recruitment and stimulation of an antitumor immune response
US6002008A (en) 1997-04-03 1999-12-14 American Cyanamid Company Substituted 3-cyano quinolines
US20020076695A1 (en) 1997-04-04 2002-06-20 Jeffrey S. Ross Methods for treating prostate cancer
US5994071A (en) 1997-04-04 1999-11-30 Albany Medical College Assessment of prostate cancer
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
PT980244E (en) 1997-05-06 2003-10-31 Wyeth Corp Utilization of quinazoline compounds for the treatment of the renal polycystic disease
AU757627B2 (en) 1997-06-24 2003-02-27 Genentech Inc. Methods and compositions for galactosylated glycoproteins
TW436485B (en) 1997-08-01 2001-05-28 American Cyanamid Co Substituted quinazoline derivatives
AU9805398A (en) 1997-10-15 1999-05-03 Children's Medical Center Corporation Novel human egf receptors and use thereof
AT419009T (en) 1997-10-31 2009-01-15 Genentech Inc Methods and compositions containing glycoprotein glycor forms
AU1308799A (en) 1997-11-06 1999-05-31 American Cyanamid Company Use of quinazoline derivatives as tyrosine kinase inhibitors for treating colonic polyps
ZA9811162B (en) 1997-12-12 2000-06-07 Genentech Inc Treatment with anti-ERBB2 antibodies.
RS49779B (en) * 1998-01-12 2008-06-05 Glaxo Group Limited, Byciclic heteroaromatic compounds as protein tyrosine kinase inhibitors
US6358682B1 (en) 1998-01-26 2002-03-19 Ventana Medical Systems, Inc. Method and kit for the prognostication of breast cancer
US6417168B1 (en) 1998-03-04 2002-07-09 The Trustees Of The University Of Pennsylvania Compositions and methods of treating tumors
DE69938923D1 (en) 1998-03-27 2008-07-31 Genentech Inc ligand synergy between apo-2 and antibodies against her-2
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
CA2323757C (en) 1998-04-02 2011-08-02 Genentech, Inc. Antibody variants and fragments thereof
JP4334141B2 (en) 1998-04-20 2009-09-30 グリカート バイオテクノロジー アクチェンゲゼルシャフト Engineering glycosylation of antibodies to improve antibody-dependent cytotoxicity
US7244826B1 (en) 1998-04-24 2007-07-17 The Regents Of The University Of California Internalizing ERB2 antibodies
DK1075488T4 (en) 1998-05-06 2013-10-21 Genentech Inc Protein purification by ion exchange chromatography
CA2332331A1 (en) 1998-05-15 1999-11-25 Francisco Robert Treatment of human tumors with radiation and inhibitors of growth factor receptor tyrosine kinases
US6040498A (en) 1998-08-11 2000-03-21 North Caroline State University Genetically engineered duckweed
US6573043B1 (en) 1998-10-07 2003-06-03 Genentech, Inc. Tissue analysis and kits therefor
EP1131304B1 (en) 1998-11-19 2002-12-04 Warner-Lambert Company N- 4-(3-chloro-4-fluoro-phenylamino)-7-(3-morpholin-4-yl-propoxy)-quinazolin-6-yl]-acrylamide, an irreversible inhibitor of tyrosine kinases
PL220113B1 (en) 1999-01-15 2015-08-31 Genentech Inc. Variant of parent polypeptide comprising the Fc region, polypeptide comprising a variant of the Fc region with altered binding affinity of Fc gamma receptor (FcγR), a polypeptide comprising the variant of Fc region with altered binding affinity of neonatal Fc receptor (FcRn), a composition, isolated nucleic acid, vector, host cell, method for preparing the polypeptide variant, the use of the polypeptide variant and method for preparing a the Fc region variant
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
DE60041808D1 (en) 1999-01-27 2009-04-30 Cornell Res Foundation Inc Treatment of cancer with her-2 / neu overexprimation
US6333348B1 (en) 1999-04-09 2001-12-25 Aventis Pharma S.A. Use of docetaxel for treating cancers
US6316462B1 (en) 1999-04-09 2001-11-13 Schering Corporation Methods of inducing cancer cell death and tumor regression
CA2369292C (en) 1999-04-09 2010-09-21 Kyowa Hakko Kogyo Co. Ltd. Method of modulating the activity of functional immune molecules
IL146480D0 (en) * 1999-05-14 2002-07-25 Imclone Systems Inc Treatment of refractory human tumors with epidermal growth factor receptor antagonists
AU782325B2 (en) 1999-05-14 2005-07-21 Genentech Inc. Treatment with anti-ErbB2 antibodies
AUPQ105799A0 (en) 1999-06-18 1999-07-08 Victor Chang Cardiac Research Institute, The Cell growth inhibition
US20030086924A1 (en) 1999-06-25 2003-05-08 Genentech, Inc. Treatment with anti-ErbB2 antibodies
DK1189634T3 (en) 1999-06-25 2007-06-25 Genentech Inc Treatment of prostate cancer with anti-ErbB2 antibodies
US6949245B1 (en) * 1999-06-25 2005-09-27 Genentech, Inc. Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies
US20040013667A1 (en) 1999-06-25 2004-01-22 Genentech, Inc. Treatment with anti-ErbB2 antibodies
GB2368796B (en) 1999-06-25 2004-08-04 Genentech Inc Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies
PT2283866E (en) 1999-06-25 2015-07-20 Genentech Inc Methods of treatment using anti-erbb antibody-maytansinoid conjugates
GB9917012D0 (en) 1999-07-20 1999-09-22 Pharmacia & Upjohn Spa Combined preparations comprising antitumor agents
WO2001009187A2 (en) 1999-07-29 2001-02-08 Medarex, Inc. Human monoclonal antibodies to her2/neu
KR20110008112A (en) 1999-08-27 2011-01-25 제넨테크, 인크. Dosages for treatment with anti-erbb2 antibodies
AU7710300A (en) 1999-09-22 2001-04-24 Corixa Corporation Methods for diagnosis and therapy of hematological and virus-associated malignancies
WO2001025454A2 (en) 1999-10-04 2001-04-12 Medicago Inc. Method for regulating transcription of foreign genes in the presence of nitrogen
US7125978B1 (en) 1999-10-04 2006-10-24 Medicago Inc. Promoter for regulating expression of foreign genes
JP4668498B2 (en) 1999-10-19 2011-04-13 協和発酵キリン株式会社 Method for producing polypeptide
GB9925958D0 (en) 1999-11-02 1999-12-29 Bundred Nigel J Therapeutic use
WO2001053354A2 (en) 2000-01-20 2001-07-26 Chiron Corporation Methods for treating tumors using a fusion protein comprising il-2- polypeptides and p185-specific binding molecules
JP2003525252A (en) 2000-02-29 2003-08-26 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ Her2 antibody and of farnesyl protein transferase inhibitor combination
US7097840B2 (en) 2000-03-16 2006-08-29 Genentech, Inc. Methods of treatment using anti-ErbB antibody-maytansinoid conjugates
US6632979B2 (en) 2000-03-16 2003-10-14 Genentech, Inc. Rodent HER2 tumor model
US6767541B2 (en) 2000-03-20 2004-07-27 The Regents Of The University Of California HER-2/neu overexpression abrogates growth inhibitory pathways
GB0008368D0 (en) 2000-04-06 2000-05-24 Astrazeneca Ab Combination product
EP1275398A4 (en) 2000-04-06 2004-09-01 Kyowa Hakko Kogyo Kk Diagnostics and remedies for rheumatoid arthritis
AU4761601A (en) * 2000-04-11 2001-10-23 Genentech Inc Multivalent antibodies and uses therefor
US7306801B2 (en) 2000-05-15 2007-12-11 Health Research, Inc. Methods of therapy for cancers characterized by overexpression of the HER2 receptor protein
EP1282440A1 (en) 2000-05-15 2003-02-12 Pharmacia & Italia S.p.A. Aromatase inhibitors and monoclonal anti-her2 antibodies as antitumor agents
ES2331646T3 (en) 2000-05-19 2010-01-12 Genentech, Inc. Test for the detection of genes to improve the probability of an effective answer to a therapy against cancer based on erbb antagonists.
GB0017635D0 (en) 2000-07-18 2000-09-06 Pharmacia & Upjohn Spa Antitumor combined therapy
TWI317285B (en) 2000-07-28 2009-11-21 Dainippon Sumitomo Pharma Co New use and kit for remedies for cancer
JP2004527456A (en) 2000-08-09 2004-09-09 イムクローン システムズ インコーポレイティド Treatment of hyperproliferative disorders by Egf receptor antagonists
US6984494B2 (en) 2000-08-15 2006-01-10 Genentech, Inc. Analytical method
US20020119148A1 (en) * 2000-09-01 2002-08-29 Gerritsen Mary E. ErbB4 antagonists
CA2953239A1 (en) 2000-10-06 2002-04-18 Kyowa Hakko Kirin Co., Ltd. Antibody composition-producing cell
US6946292B2 (en) 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
US7064191B2 (en) 2000-10-06 2006-06-20 Kyowa Hakko Kogyo Co., Ltd. Process for purifying antibody
US20020142328A1 (en) 2000-12-01 2002-10-03 Danenberg Kathleen D. Method of determining a chemotherapeutic regimen by assaying gene expression in primary tumors
KR100946980B1 (en) 2000-12-01 2010-03-17 리스판스 지네틱스, 인크. Method of determining epidermal growth factor receptor and her2-neu gene expression and correlation of levels thereof with survival rates
US6602670B2 (en) 2000-12-01 2003-08-05 Response Genetics, Inc. Method of determining a chemotherapeutic regimen based on ERCC1 expression
AU3948602A (en) 2000-12-08 2002-06-18 Uab Research Foundation Combination radiation therapy and chemotherapy in conjuction with administrationof growth factor receptor antibody
BR0116575A (en) 2001-01-09 2004-01-06 Merck Patent Gmbh Combination therapy using receptor tyrosine kinase inhibitors and angiogenesis inhibitors
EP1228766A1 (en) 2001-01-31 2002-08-07 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. PYK2 phosphorylation by HER3 induces tumor invasion
US7005278B2 (en) 2001-03-02 2006-02-28 Danenberg Kathleen D Method of determining dihydropyrimidine dehydrogenase gene expression
WO2002081649A2 (en) * 2001-04-06 2002-10-17 The Trustees Of The University Of Pennsylvania ErbB INTERFACE PEPTIDOMIMETICS AND METHODS OF USE THEREOF
WO2002087619A1 (en) 2001-04-27 2002-11-07 Takeda Chemical Industries, Ltd. Preventive/therapeutic method for cancer
US6884869B2 (en) 2001-04-30 2005-04-26 Seattle Genetics, Inc. Pentapeptide compounds and uses related thereto
KR20040029975A (en) 2001-05-08 2004-04-08 메르크 파텐트 게엠베하 Combination therapy using anti-egfr antibodies and anti-hormonal agents
US6582919B2 (en) 2001-06-11 2003-06-24 Response Genetics, Inc. Method of determining epidermal growth factor receptor and HER2-neu gene expression and correlation of levels thereof with survival rates
CN1678634A (en) * 2002-06-28 2005-10-05 多曼蒂斯有限公司 Immunoglobulin single variable antigen combination area and its opposite constituent
ITRM20010408A1 (en) 2001-07-10 2003-01-10 Univ Napoli Federico Ii Mini-human antibody cytotoxic to cancer cells that express the ErbB2 receptor.
KR20040054669A (en) 2001-08-03 2004-06-25 글리카트 바이오테크놀로지 아게 Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity
US7662374B2 (en) * 2001-08-03 2010-02-16 The Trustees Of The University Of Pennsylvania Monoclonal antibodies to activated erbB family members and methods of use thereof
EP1283053A1 (en) 2001-08-09 2003-02-12 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Inhibitors of HER3 activity
US20030068318A1 (en) 2001-09-28 2003-04-10 O'brien Timothy Treatment of uterine serous papillary cancer
IL161412D0 (en) 2001-10-25 2004-09-27 Genentech Inc Glycoprotein compositions
US20030096823A1 (en) 2001-11-16 2003-05-22 Beryl Asp Method for the treatment of cardiotoxicity induced by antitumor compounds
US20040093621A1 (en) 2001-12-25 2004-05-13 Kyowa Hakko Kogyo Co., Ltd Antibody composition which specifically binds to CD20
US20030175845A1 (en) 2002-03-13 2003-09-18 Kalbag Suresh M. Use of sulfitolysis in high performance peptide mapping
US7332580B2 (en) * 2002-04-05 2008-02-19 The Regents Of The University Of California Bispecific single chain Fv antibody molecules and methods of use thereof
US7332585B2 (en) * 2002-04-05 2008-02-19 The Regents Of The California University Bispecific single chain Fv antibody molecules and methods of use thereof
JP2005534623A (en) 2002-04-08 2005-11-17 スミスクライン ビーチャム コーポレーション Method of treating cancer comprising administering an inhibitor and raf and / or ras inhibitor Erb family
CA2481656A1 (en) 2002-04-09 2003-10-16 Yutaka Kanda Cells in which activity of the protein involved in transportation of gdp-fucose is reduced or lost
WO2003085119A1 (en) 2002-04-09 2003-10-16 Kyowa Hakko Kogyo Co., Ltd. METHOD OF ENHANCING ACTIVITY OF ANTIBODY COMPOSITION OF BINDING TO FcϜ RECEPTOR IIIa
EP1500400A4 (en) 2002-04-09 2006-10-11 Kyowa Hakko Kogyo Kk Drug containing antibody composition
JP4832719B2 (en) 2002-04-09 2011-12-07 協和発酵キリン株式会社 Medicine containing antibody composition for FcγRIIIa polymorphism patients
AU2003236015A1 (en) 2002-04-09 2003-10-20 Kyowa Hakko Kirin Co., Ltd. Process for producing antibody composition
CN102911987B (en) 2002-04-09 2015-09-30 协和发酵麒麟株式会社 Genome is modified cells
JP2005522514A (en) 2002-04-10 2005-07-28 ジェネンテック・インコーポレーテッドGenentech,Inc. Anti-her2 antibody variants
ITTO20020340A1 (en) 2002-04-19 2003-10-20 Biother Di Contardi Gabriella Localization of the HER2 receptor using biotinylated humanized antibody.
US20030202973A1 (en) 2002-04-29 2003-10-30 Dr. George Pieczenik Treatment of refractory human tumors with epidermal growth factor receptor and HER1 mitogenic ligand (EGFRML) antagonists
NZ556507A (en) 2002-06-03 2010-03-26 Genentech Inc Synthetic antibody phage libraries
JP5069843B2 (en) 2002-07-15 2012-11-07 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト Method for identifying tumors responsive to treatment with anti-ErbB2 antibodies
EP1391213A1 (en) 2002-08-21 2004-02-25 Boehringer Ingelheim International GmbH Compositions and methods for treating cancer using maytansinoid CD44 antibody immunoconjugates and chemotherapeutic agents
EP3388452A3 (en) 2002-09-11 2019-02-20 Genentech, Inc. Protein purification
JP2006505546A (en) 2002-10-10 2006-02-16 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフトングMerck Patent Gesellschaft mit beschraenkter Haftung Its use in the bispecific anti-ErbB antibodies and tumor therapy
US7361740B2 (en) 2002-10-15 2008-04-22 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
WO2004048525A2 (en) 2002-11-21 2004-06-10 Genentech, Inc. Therapy of non-malignant diseases or disorders with anti-erbb2 antibodies
EP3263596A1 (en) 2002-12-16 2018-01-03 Genentech, Inc. Immunoglobulin variants and uses thereof
WO2004087207A2 (en) 2003-03-27 2004-10-14 Georgetown University Method for inducing apoptosis and aneuploidy regression in cancer cells
KR20190085166A (en) 2003-05-30 2019-07-17 제넨테크, 인크. Treatment with anti-VEGF antibodies
WO2005016347A1 (en) * 2003-08-18 2005-02-24 Pfizer Products Inc. Dosing schedule for erbb2 anticancer agents
CA2542046A1 (en) 2003-10-08 2005-04-21 Kyowa Hakko Kogyo Co., Ltd. Fused protein composition
US20070134759A1 (en) 2003-10-09 2007-06-14 Harue Nishiya Process for producing antibody composition by using rna inhibiting the function of alpha1,6-fucosyltransferase
SI2380911T1 (en) 2003-11-05 2018-07-31 Roche Glycart Ag Antigen binding molecules with increased Fc receptor binding affinity and effector function
WO2005053742A1 (en) 2003-12-04 2005-06-16 Kyowa Hakko Kogyo Co., Ltd. Medicine containing antibody composition
DK1737891T3 (en) 2004-04-13 2013-03-25 Hoffmann La Roche Anti-P-selectin antibodies
RU2433831C2 (en) * 2004-05-05 2011-11-20 Мерримак Фармасьютикалз, Инк. Bispecific binding agents for modulating biological activity
TWI309240B (en) 2004-09-17 2009-05-01 Hoffmann La Roche Anti-ox40l antibodies
HUE030079T2 (en) 2004-09-23 2017-04-28 Genentech Inc Cysteine engineered antibodies and conjugates
EP1838735A2 (en) 2004-12-31 2007-10-03 Genentech, Inc. Polypeptides that bind br3 and uses thereof
KR20150083139A (en) * 2005-01-21 2015-07-16 제넨테크, 인크. Fixed dosing of her antibodies
US20090246206A1 (en) * 2005-02-23 2009-10-01 Merrimack Pharmaceuticals, Inc. Bispecific binding agents for modulating biological activity
PE02072007A1 (en) * 2005-07-22 2007-03-09 Genentech Inc Combined treatment of tumors expressing her
WO2007042289A2 (en) * 2005-10-11 2007-04-19 Ablynx N.V. Nanobodies™ and polypeptides against egfr and igf-ir
AR056857A1 (en) 2005-12-30 2007-10-24 U3 Pharma Ag Antibodies directed to HER-3 (human factor receptor-3 epidermal growth) and their uses
ES2399075T3 (en) * 2006-08-30 2013-03-25 Genentech, Inc. multispecific antibodies
AU2007353412A1 (en) * 2006-11-21 2008-11-20 Fox Chase Cancer Center Anti-EGFR family antibodies, bispecific anti-EGFR family antibodies and methods of use thereof
US20080226635A1 (en) 2006-12-22 2008-09-18 Hans Koll Antibodies against insulin-like growth factor I receptor and uses thereof
WO2008100624A2 (en) * 2007-02-16 2008-08-21 Merrimack Pharmaceuticals, Inc. Antibodies against erbb3 and uses thereof
GB0807018D0 (en) 2008-04-17 2008-05-21 Fusion Antibodies Ltd Antibodies and treatment
EP2138511A1 (en) * 2008-06-27 2009-12-30 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. HER3 as a determinant for the prognosis of melanoma
MY152068A (en) * 2009-03-20 2014-08-15 Genentech Inc Bispecific anti-her antibodies
KR20110124369A (en) 2009-04-07 2011-11-16 로슈 글리카트 아게 Bispecific anti-erbb-3/anti-c-met antibodies
CA2780935A1 (en) * 2009-11-13 2011-05-19 U3 Pharma Gmbh Material and methods for treating or preventing her-3 associated diseases
WO2011076683A1 (en) 2009-12-22 2011-06-30 Roche Glycart Ag Anti-her3 antibodies and uses thereof
JP2012016491A (en) 2010-07-08 2012-01-26 Panasonic Electric Works Co Ltd Reciprocating electric shaver
JP2015514710A (en) * 2012-03-27 2015-05-21 ジェネンテック, インコーポレイテッド Diagnosis and treatment of HER3 inhibitors
CA2902913A1 (en) * 2013-03-14 2014-10-02 Genentech, Inc. Predicting response to egfr inhibitors

Also Published As

Publication number Publication date
RU2504553C2 (en) 2014-01-20
EP2408817A1 (en) 2012-01-25
IL233563D0 (en) 2014-08-31
HK1165809A1 (en) 2015-04-10
IL214827D0 (en) 2011-11-30
MX2011009729A (en) 2011-10-14
KR20150036824A (en) 2015-04-07
TW201438739A (en) 2014-10-16
CL2011002304A1 (en) 2012-04-09
JP5624114B2 (en) 2014-11-12
RU2011142281A (en) 2013-04-27
TWI461211B (en) 2014-11-21
WO2010108127A1 (en) 2010-09-23
PE05392012A1 (en) 2012-05-12
UA106070C2 (en) 2014-07-25
CA2755640A1 (en) 2010-09-23
CA2755640C (en) 2018-05-22
AU2010226453B2 (en) 2013-11-21
ES2572728T3 (en) 2016-06-02
NZ594665A (en) 2013-08-30
US8597652B2 (en) 2013-12-03
US20120121596A1 (en) 2012-05-17
US20100255010A1 (en) 2010-10-07
TW201544123A (en) 2015-12-01
CO6430487A2 (en) 2012-04-30
KR20130080871A (en) 2013-07-15
JP2014158481A (en) 2014-09-04
BRPI1006215A2 (en) 2019-09-24
AU2010226453A1 (en) 2011-09-08
KR20110117256A (en) 2011-10-26
US9327035B2 (en) 2016-05-03
MA33198B1 (en) 2012-04-02
AR075896A1 (en) 2011-05-04
JP2012521196A (en) 2012-09-13
CN104447995A (en) 2015-03-25
KR101362522B1 (en) 2014-02-14
CN102356092A (en) 2012-02-15
CR20110496A (en) 2011-12-06
EP2408817B1 (en) 2016-03-16
US20140193414A1 (en) 2014-07-10
ECSP11011338A (en) 2011-10-31
EP3088420A1 (en) 2016-11-02
HK1205155A1 (en) 2015-12-11
ZA201106127B (en) 2014-03-26
RU2013146469A (en) 2015-04-27
TW201036637A (en) 2010-10-16
CN102356092B (en) 2014-11-05
MY152068A (en) 2014-08-15
IL214827A (en) 2016-10-31
SG174378A1 (en) 2011-10-28
US20140056899A1 (en) 2014-02-27

Similar Documents

Publication Publication Date Title
DK2443154T3 (en) Bispecific anti-anti-binding proteins
PT2358755E (en) C-met antibodies
ZA201106503B (en) Antibody formulation
HK1220188A1 (en) Novel benzodiazepine compound
HUE038727T2 (en) Anti-cd38 antibodies
ZA200906345B (en) Anti-sclerostin antibodies
BRPI1014474A2 (en) bispecific antibodies anti-erbb-1 / anti-c-met.
EP2424368A4 (en) Pyrrolotriazine compounds
IL206108D0 (en) Bivalent, bispecific antibodies
IL205285D0 (en) Bivalent, bispecific antibodies
IL206161D0 (en) Bivalent, bispecific antibodies
IL205750D0 (en) Bivalent, bispecific antibodies
HRP20181320T1 (en) Human anti-tau antibodies
IL205906D0 (en) Antigen-binding constructs
SI2853545T1 (en) Antibody specific for IgE
HUE040213T2 (en) Anti-tim-3 antibody
PL2552966T3 (en) Antibodies against csf-1r
SI2356153T1 (en) Cross-species-specific psmaxcd3 bispecific single chain antibody
BRPI0906877A2 (en) Improved anti-trkb antibodies
IL222272A (en) Anti-erbb3 antibodies
SI2344537T1 (en) Bispecific anti-vegf/anti-ang-2 antibodies
IL221408D0 (en) Monoclonal antibodies against c-met
EP2409990A4 (en) Antibody constant region variant
IL214884D0 (en) Trivalent, bispecific antibodies
GB0708002D0 (en) Antibodies